Cancer is the leading cause of death worldwide, and its treatment and outcomes have been
dramatically revolutionised by targeted therapies. As the most frequently mutated oncogene …

Oncogenic KRAS mutations are the most frequent mutations in human cancer, but most
difficult to target. While sustained proliferation caused by oncogenic KRAS-downstream …

Tumor molecular profiling is a fundamental component of precision oncology, enabling the
identification of genomic alterations in genes and pathways that can be targeted …

Pancreatic ductal adenocarcinoma (PDAC) is projected to become the second deadliest
cancer in the United States by 2025, with 5-year survival at less than 10%. In other …

KRAS-driven lung cancers frequently inactivate TP53 and/or STK11/LKB1, defining tumor
subclasses with emerging clinical relevance. Specifically, KRAS-LKB1 (KL)–mutant lung …

Ex vivo systems that incorporate features of the tumor microenvironment and model the
dynamic response to immune checkpoint blockade (ICB) may facilitate efforts in precision …

RAS genes are the most commonly mutated oncogenes in cancer, but effective therapeutic
strategies to target RAS-mutant cancers have proved elusive. A key aspect of this challenge …

Despite more than three decades of intensive effort, no effective pharmacological inhibitors
of the RAS oncoproteins have reached the clinic, prompting the widely held perception that …

STK11/LKB1 is among the most commonly inactivated tumor suppressors in non–small cell
lung cancer (NSCLC), especially in tumors harboring KRAS mutations. Many oncogenes …

KRAS is a frequent oncogenic driver in solid tumors, including non-small cell lung cancer
(NSCLC). It was previously thought to be an" undruggable" target due to the lack of deep …